IN BRIEF: MyHealthChecked swings to annual profit on nasal Covid swab

Archived article

Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.

MyHealthChecked PLC - Cardiff-based healthcare company - Swings to annual pretax profit of £2.0 million in 2021, versus a loss of £3.8 million in 2020. Revenue surges to £16.4 million from £50,000 in 2020.

‘The main driver of commercial success was the roll-out of our new Covid-19 PCR nasal swab test kit for at-home use which was adopted by the UK's top two high street pharmacy retailers,’ firm says.

In 2022, the company's key focus is to launch a portfolio of five new wellness tests and build upon a digital platform. They will focus on weight management, vitamin deficiency, food intolerances, heart health and blood glucose. ‘This portfolio will grow as we enter the third quarter and the fourth quarter and will be channelled initially through our direct-to-consumer model,’ Chair Adam Reynolds says. ‘We look forward to delivering further growth and value to shareholders in 2022 and beyond,’ he adds.

Current stock price: 1.78 pence, up 4.9% on Tuesday

12-month change: down 54%

Copyright 2022 Alliance News Limited. All Rights Reserved.